Quantcast

Latest Novartis AG Stories

2010-12-01 00:04:00

EAST HANOVER, N.J., Dec. 1, 2010 /PRNewswire/ -- With more than 170 presentations focused on its marketed and pipeline compounds at key oncology medical congresses in December, Novartis continues to demonstrate progress of its innovative research and development efforts, collaboration with the scientific community and commitment to patients with cancer and rare diseases(1,2). The American Society of Hematology (ASH) annual meeting in Orlando, FL (December 4-7) will feature 30 oral...

b7bc62dffd258f9db4937b526bef450d1
2010-11-09 12:45:00

Novartis AG is trying to receive regulatory approval within 18 months for a tablet that contains an embedded microchip. The program will use the Swiss firm's established drugs taken by transplant patients to avoid organ rejection.  However, Trevor Mundel, head of global development, believes the concept can be applied to many other pills. "We are taking forward this transplant drug with a chip and we hope within the next 18 months to have something that we will be able to submit to the...

2010-11-03 16:08:00

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical...

2010-10-27 15:37:00

PRINCETON, N.J., Oct. 27 /PRNewswire/ -- Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number...

2010-10-27 09:44:00

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Novartis announced today that it will add 300 new jobs and invest $600 million over the next five years to expand its global Research headquarters campus on Massachusetts Avenue in Cambridge, Mass. "Novartis was the first global pharmaceutical company to move its Research headquarters to Massachusetts just a few years ago. It has achieved prominence and, we believe, helped to amplify Cambridge's magnetism for others in the biomedical field to...

2010-10-16 15:45:00

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada. The study showed that Reclast maintained bone mass in...

2010-10-07 06:00:00

EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis. Gilenya was approved by the US Food and Drug Administration (FDA) on September 21, 2010. For people with MS and healthcare professionals seeking information about Gilenya, Novartis offers free programs to learn about educational...

2010-09-22 00:30:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line treatment for relapsing forms of multiple sclerosis - the most common forms of the disease. The FDA approval makes Gilenya the first oral treatment indicated for relapsing forms of MS available in the US. To view the multimedia assets associated with this release,...

2010-09-22 00:27:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine...

2010-09-15 08:31:00

CHICAGO, Sept. 15 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for WMT, CMCSA, GPS, NVS, and CROX. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/091510A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Wal-Mart Stores Inc. (NYSE: WMT), Comcast Corporation (Nasdaq:...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related